MarketLens
Sign Up

Hims & Hers' Peptide Rally: A Premature Celebration of Regulatory Progress

4 months ago
SHARE THIS ON:

Hims & Hers' Peptide Rally: A Premature Celebration of Regulatory Progress

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•4 months ago

QUICK SPARK: Martin Shkreli Shorts Hims & Hers Stock, Says 'Peptides Are Fake Medicine'

Martin Shkreli disclosed a short position in Hims & Hers Health (HIMS), calling its peptide products 'fake medicine.' The move adds a high-profile bearish voice to the stock.
Stock News•4 months ago

Hims & Hers stands to gain if the FDA loosens restrictions on peptides

Hims & Hers Health could access a multi-billion-dollar peptide market if the FDA loosens manufacturing restrictions, per analysts.
Stock News•4 months ago

HIMS Breakout Signals Structural Business Transformation

HIMS stock surged from below $14 to above $37 after a regulatory shock, driven by over 100,000 monthly weight-loss subscriber additions and a diversified growth narrative.

Breaking News

View All →

Top Headlines

View More →
Stock News•2 hours ago

Cisco Stock Fell 15.5% Despite Its Strongest Growth in 15 Years. Is the Dividend Safe?

Stock News•2 hours ago

Prediction: This Will Be Nvidia's Stock Price in 2027 After Its Phenomenal Q3 Results

Stock News•2 hours ago

GOOGL, GOOG FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important December 1 Deadline in Securities Class Action - GOOGL, GOOG

Stock News•3 hours ago

The S&P 500 Is Now Below Every Wall Street Year-End Target for 2026

Stock News•3 hours ago

The S&P 500 Is Having the Longest Losing Streak Since February 2020